OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody

BACKGROUND: Anti-PD-1 monoclonal antibody, nivolumab, has shown efficacy for advanced gastric cancer (AGC). However, the specific immune cell subsets predominantly activated during the period of anti-PD-1 therapy for AGC have not been clarified. METHODS: Peripheral blood of 30 AGC patients treated w...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohmura, Hirofumi, Yamaguchi, Kyoko, Hanamura, Fumiyasu, Ito, Mamoru, Makiyama, Akitaka, Uchino, Keita, Shimokawa, Hozumi, Tamura, Shingo, Esaki, Taito, Mitsugi, Kenji, Shibata, Yoshihiro, Oda, Hisanobu, Tsuchihashi, Kenji, Ariyama, Hiroshi, Kusaba, Hitoshi, Oda, Yoshinao, Akashi, Koichi, Baba, Eishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217874/
https://www.ncbi.nlm.nih.gov/pubmed/32203221
http://dx.doi.org/10.1038/s41416-020-0810-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217874/
https://www.ncbi.nlm.nih.gov/pubmed/32203221
http://dx.doi.org/10.1038/s41416-020-0810-1

Ejemplares similares